Almirall, S.A. (FRA:E2Z)

Market Cap	2.75B +41.0%
Revenue (ttm)	1.11B +12.5%
Net Income	46.15M +354.9%
EPS	0.22 +354.9%
Shares Out	n/a
PE Ratio	59.66
Forward PE	31.46
Dividend	0.15 (1.17%)
Ex-Dividend Date	May 15, 2025

Volume	n/a
Average Volume	89
Open	12.78
Previous Close	12.74
Day's Range	12.78 - 12.78
52-Week Range	9.30 - 13.72
Beta	n/a
RSI	56.36
Earnings Date	May 11, 2026

About Almirall

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal sys...

• Industry: Pharmaceutical Preparations
• Founded: 1943
• Employees: 2,108
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: E2Z

Financial Performance

In 2025, Almirall's revenue was 1.11 billion, an increase of 12.51% compared to the previous year's 990.63 million. Earnings were 46.15 million, an increase of 354.85%.